Harvard Bioscience (HBIO) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HBIO Hot Sheet
Price: $8.61 --0%
Revenue Growth %: +6.1%
Financial Fact:
Amortization of intangible assets: 729K
Today's EPS Names:
KEEL, SENEA, XFOR, More
Revenue Growth %: +6.1%
Financial Fact:
Amortization of intangible assets: 729K
Today's EPS Names:
KEEL, SENEA, XFOR, More
Join SI Premium – FREE
Harvard Bioscience (NASDAQ: HBIO) reported Q4 EPS of $0.05, $0.03 better than the analyst estimate of $0.02. Revenue for the quarter came in at $27 million versus the consensus estimate of $26 million.
For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verisk Analytics (VRSK) Tops Q3 EPS by 3c; Offers Guidance
- Nextdoor Holdings, Inc. (NXDR) reported Q3 Revenue ; Offers Guidance
- Fate Therapeutics (FATE) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
